Pharm
Desmopressin
search
Desmopressin
, dDAVP, Synthetic Hormone Arginine Vasopressin, Synthetic Vasopressin, Noctiva
See Also
Sodium and Water Homeostasis
Antidiuretic Hormone
Diabetes Insipidus
Primary
Nocturnal Enuresis
Nocturia
Hemophilia A
Von Willebrand's Disease
Indications
Diabetes Insipidus
Control of
Hemophilia A
related bleeding
Primary
Nocturnal Enuresis
Nocturia
(non-medication options are preferred)
Von Willebrand's Disease
Type I (and in Type 2N) cases prior to surgery and in cases of
Trauma
Other VWD forms (Type 2, Type 3 and pseudo-VWF) will not respond to DDAVP
May have paradoxical lowering of VWF
Contraindications
Hyponatremia
eGFR <50 ml/min
Conditions predisposing to
Hyponatremia
See
Drug Interaction
s below (e.g.
Diuretic
s, steroids,
SSRI
,
NSAID
S)
Caution in age >65 years (higher risk for
Hyponatremia
)
Impaired
Renal Function
Congestive Heart Failure
Polydipsia
Mechanism
Synthetic ADH replacement
Hormone
(analogue of
Vasopressin
)
Potent antidiuretic
No
Vasopressor
activity
Urine Volume
decreases by resorbing water at distal renal tubules
Increases release of
Von Willebrand Factor
Protein
(stored in Weibel-Palade bodies)
Pharmacokinetics
Duration of action: 12 hours
Precautions
Limit fluid intake for at least 8 hours overnight (when used for
Nocturnal Enuresis
,
Nocturia
)
Avoid drinking water before bed (and avoid overnight water ingestion)
Educate patients on symptoms of
Hyponatremia
(esp. age >65 years)
Nausea
or
Vomiting
Neurologic symptoms (
Headache
, confusion, lethargy,
Seizure
s)
Dosing
Nocturnal Enuresis
Gene
ral
If effective, may continue for 3-6 months
Maintain dose for 4-6 weeks and then slowly taper off over 6 months
Discontinue slowly (e.g. 10 mcg/month)
Reduces risk of relapse
Consider in combination with
Bed-Wetting Alarm
or
Oxybutynin
Desmopressin Intranasal (standard, high dose)
Not recommended due to risk of
Hyponatremia
(from
Water Intoxication
)
Initial: 5 mcg spray each nostril qhs
Increase as needed up to 20 mcg each nostril qhs
Desmopressin Oral
Initial: 0.2 mg orally at bedtime
Use lowest effective dose
Increase as needed to 0.6 mg at bedtime
Dosing
Nocturia
in Adults
Gene
ral
Lower doses are more effective in women
Other non-medication approaches are preferred for
Nocturia
(or specific treatments)
Desmopressin Intranasal (Noctiva, low dose)
Each spray delivers 0.83 mcg
Start at 1 spray in each nostril at 30 min before bed
May increase to 1.66 mcg after 1 week if tolerated
Marketed for
Nocturia
in adults
Expensive: $425/month in 2018
Desmopressin Sublingual Tablet
Women: 25 mcg at 1 hour before bed
Men: 50 mcg at 1 hour before bed
Desmopressin Tablet
Take 50-100 mcg nightly at 1 hour before bed
Dosing
Diabetes Insipidus
Nasal Spray: 10-40 mcg daily (or divided 2-3 times per day)
Intranasal 5 mcg equivalent to 0.1 mg oral
Oral Tablet: 0.05 to 1.2 mg orally daily (or divided 2-3 times daily)
Subcutaneous or IV: 2-4 mcg/day IV/SC divided twice daily
Dosing
Von Willebrand Disease
or
Hemophilia A
IV: 0.3 mcg/kg IV over 15 to 30 minutes
Intranasal concentrated dDAVP (Stimate)
Weight <50kg: 150 mcg intranasally (1 spray in SINGLE nostril)
Weight >50kg: 300 mcg intranasally (1 spray EACH nostril)
Pharmacokinetics
specific to VWF release
Onset of action within 30-60 minutes with duration of 6-12 hours
Do not repeat more often than every 24 to 48 hours due to
Hyponatremia
risk (as well as tachyphylaxis)
Adverse Effects
Nasal irritation or
Epistaxis
with nasal spray
Behavior changes
Aggressive behavior
Nightmare
s
Nocturia
Administer at night to reduce
Nocturia
Severe
Hyponatremia
(
Water Intoxication
)
Seizure
s (with high dose Desmopressin nasal sprays)
Expensive
Drug Interactions
Increased risk of
Hyponatremia
Diuretic
s
Corticosteroid
s (inhaled or systemic)
Selective Serotonin Reuptake Inhibitor
s (
SSRI
)
Chronic
NSAID
s
Labs
Monitoring
Serum Sodium
Obtain baseline, at 7 days, 30 days and periodically (esp. after dose changes)
Efficacy
Nocturnal Enuresis
Most effective in over age 8-9 years (60-70% respond)
Also more effective if only a few wet nights and normal
Bladder
capacity
High relapse rate (>80%); Reduced if slowly tapered - see doing above
References
Deloughery and Orman in Majoewsky (2013) EM:Rap 13(9): 1-4
Getaneh (2025) Am Fam Physician 111(6): 515-23 [PubMed]
Tullus (1999) Acta Paediatr 88:1274-8 [PubMed]
Kruse (2001) BJU Int 88:572-6 [PubMed]
Robson (2007) J Urol 178: 24-30 [PubMed]
Type your search phrase here